When entering the Title of your abstract, keep in mind that the abstract is limited to a total of 2,140 characters (not including spaces), INCLUDING the abstract title.

Author information does not count towards the character limit.

The authors included should be those who contribute significantly to the intellectual content of the abstract (maximum 50 authors). When adding authors to your abstract, the Full Name, Degree, Affiliation, and Email Address of each author must be included. You will be able to use the ISHLT database search tool on the submission site to search and add your authors. Authors will be listed in the author block in the order they are added but can be rearranged after adding.

The Submitting Author is responsible for notifying all named co-authors that they will be listed as a co-author on a submitted abstract.

The Presenting Author will be the only author to receive notification of acceptance/rejection of a submitted abstract; therefore, it is the Presenting Author's responsibility to notify all co-authors regarding the outcome of an abstract submission. If the abstract is accepted for presentation at the ISHLT2024 Annual Meeting, the Presenting Author must register for the meeting and attend in person. If a change in Presenting Author must be made after the submission deadline, the Presenting Author will be given the opportunity to do so in January 2024.

Your abstract may be submitted into only one category. Submission of the same abstract into multiple categories is not permitted. Submission of one study as several different abstracts is also not permitted. If the abstracts in question are not different enough to be considered separate studies, or if the same abstract is submitted into multiple categories, all versions may be rejected.

Abstract Submission Categories are separated into four Core Therapies:

• ►  HEART (Advanced Heart Failure and Transplantation)
• ►  LUNG (Advanced Lung Failure and Transplantation)
• ►  MCS (Mechanical Circulatory Support)
• ►  PVD (Pulmonary Vascular Disease (PAH and CTEPH)

ABSTRACT SUBMISSION CATEGORIES:

	Advanced Heart Failure and Transplantation
■  Basic Science-Immunology, Inflammation, Biomarkers ■  Basic Science-Models of Organ Preservation, Perfusion, Regeneration, and Graft Injury ■  Basic Science-Translational Research/Genetics ■  Basic Science-Xenotransplantation/Artificial Organs ■  Cardiac Allograft Vasculopathy ■  Clinical Ex-Vivo Perfusion and Preservation/Normothermic Regional Perfusion ■  Complications Other ■  Congenital Heart Disease Management ■  COVID 19 ■  Critical Care Medicine/Peri-operative/Intra-operative Management ■  Diagnostics and Imaging ■  Donor Management (including DCD and DBD) ■  Economics, Ethics, Public Policy ■  Health Equity and Social Determinants of Health ■  Immunology, Inflammation (Clinical) ■  Infectious Diseases - Diagnostics and Complications ■  Infectious Diseases - Management and Therapeutics ■  Multi-Organ Transplant ■  Organ Allocation and Utilization ■  Other (Clinical) ■  Outcomes (Effectiveness) ■  Outcomes (Other) ■  Outcomes (Safety, Risk Prediction/Modelling) ■  Pathology ■  Patient Adherence and Self-Management ■  Patient Care Delivery and Quality Improvement ■  Patient Centered Outcomes (Symptoms, Frailty, Rehabilitation) ■  Patient Psychosocial/Quality of Life/Palliative Care ■  Pediatric Basic Science/Translational Research ■  Pediatric Heart Failure ■  Pediatric Other ■  Pediatric Outcomes ■  Pediatric Patient Selection, Organ Allocation, Donor Management ■  Pharmacology, Therapeutics, Immunosuppression ■  Primary Graft Dysfunction ■  Rejection-Antibody Mediated (AMR) ■  Rejection-Cellular ■  Translational Research/Nursing/Other
	Advanced Lung Failure and Transplantation
■  Basic Science-Immunology, Inflammation, Biomarkers ■  Basic Science-Infectious Disease (COVID and Non-COVID, Microbiome) ■  Basic Science-Models of Organ Preservation, Perfusion and Graft Injury ■  Basic Science-Translational Research/Genetics ■  Chronic Lung Allograft Dysfunction (CLAD) ■  Clinical Ex-Vivo Perfusion and Preservation ■  Diagnostics and Pathology ■  Donor Management and Organ Allocation ■  Economics, Ethics, Public Policy ■  Health Equity and Social Determinants of Health ■  Immunology, Inflammation (Clinical) ■  Immunosuppression and Desensitization Strategies (Clinical) ■  Infectious Diseases (including COVID-19) ■  Multidisciplinary Team Care Delivery (Protocols, Quality Improvement, Service Development) ■  Patient Centered Outcomes (Symptoms, Frailty, Rehabilitation) ■  Patient Psychosocial/Quality of Life/Palliative Care ■  Pediatrics ■  Perioperative Medicine ■  Primary Graft Dysfunction ■  Recipient Selection for Transplant and/or Advanced Therapies ■  Rejection (Acute) ■  Surgical Aspects of Lung Transplantation ■  Survival/Prognostication/Risk-Stratification ■  Translational Research/Nursing/Other
	Mechanical Circulatory Support
■  Arrhythmias, ICDs and Right Heart Failure ■  Basic Science-Translational Research/Genetics ■  Cardiogenic Shock (Outcomes Research/Clinical Trials) ■  Cardiogenic Shock (Pharmacotherapy/Patient Management) ■  Cardiogenic Shock (Temporary Circulatory Support) ■  Economics, Ethics, Public Policy ■  Health Equity and Social Determinants of Health ■  Hemocompatibility/Stroke/Anticoagulation/GI Bleeding ■  Infectious Complications ■  Myocardial Recovery/Pharmacotherapy ■  Novel Temporary and Durable Devices/Engineering ■  Outcomes Research-Durable Support ■  Patient Centered Outcomes (Symptoms, Frailty, Rehabilitation) ■  Patient Management/Selection for Durable Support ■  Patient Psychosocial/Quality of Life/Palliative Care ■  Pediatrics/Congenital Heart Disease/Lung Failure ■  Surgical Techniques/Perioperative Complications ■  Translational Research/Nursing/Other
	Pulmonary Vascular Disease
■  Basic Science-Translational Research/Genetics ■  Economics, Ethics, Public Policy ■  Health Equity and Social Determinants of Health ■  Innovations in Pulmonary Hypertension ■  Interventions and Devices for PH ■  Other (Clinical) ■  Patient Centered Outcomes (Symptoms, Frailty, Rehabilitation) ■  Patient Psychosocial/Quality of Life/Palliative Care ■  Pediatric Pulmonary Hypertension ■  PAH/WHO Group I ■  PH-LHD/WHO Group II ■  PH-Lung Disease/WHO Group III ■  CTEPH (including CTED)/WHO Group IV ■  Right Heart Failure (including acute or chronic) ■  RV Physiology and Imaging ■  Translational Research/Nursing/Other

You will be asked to select the Primary Practice Area most relevant to your research abstract, as well as any additional practice areas applicable.

• ►  Anesthesiology and Critical Care
• ►  Cardiology
• ►  Cardiothoracic Surgery
• ►  Infectious Diseases
• ►  Nursing and Allied Health
• ►  Pathology
• ►  Pediatrics
• ►  Pharmacy and Pharmacology
• ►  Pulmonology
• ►  Research and Immunology

Each year, the ISHLT offers eligible presenting authors the opportunity to be considered for several scientific abstract awards. Visit the Scientific Abstract Awards page for more information.

The submission site includes a series of questions to determine the presenting author’s eligibility for each scientific abstract award. Eligibility criteria for each award is listed below. If you (as submitting author) are not the presenting author, check with the presenting author on their eligibility for these awards before submission.

ELIGIBILITY CRITERIA
 

	Philip K. Caves Award
►   Candidate must be first author and presenter. ►   Candidate must be a student, resident, fellow, or scientist in training. ►   Candidate must be a current ISHLT member or be working under a current ISHLT member. ►   Candidate cannot have previously won this award.
	Early Career Scientist Award
►   Candidate must be first author and presenter. ►   Candidate must be one of the following: ■  a trainee scientist/medical student who does not hold a medical degree ■  an early career nurse ■  an early career pharmacist ►   Candidate must NOT be a post-graduate clinician or hold a faculty position. ►   This abstract must be submitted into a Basic Science category (specified in the selected abstract category title). ►   Candidate cannot have previously won this award. ►   Current ISHLT membership is NOT required.

During abstract submission, the following questions will be asked:

* Is the presenting author an employee or owner of a company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products? (Yes/No)

* Is this abstract being funding (in part or in whole) by a healthcare company? (Yes/No)

* Does this abstract involve data from an ISHLT Registry? (Yes/No)
If yes, which Registry? (select ISHLT Thoracic Transplant Registry or IMACS Registry)

* Is this abstract based on work that was funded entirely or in part by an ISHLT grant/award? (Yes/No)
If yes, enter the name of the grant/award in the space provided.

In this step, the abstract body (purpose, methods, results, and conclusions) and any tables or images are entered. Abstract submission content should include:

• ►  Brief statement of Purpose of the study (goal or hypothesis being tested)
• ►  Statement of Methods and procedures used
• ►  Summary of Results, presented in sufficient detail to support the conclusion
• ►  Conclusions

SIZE LIMIT

• ►  2140 characters (spaces are ignored)
• ►  Includes characters in the Abstract Title, Abstract Body, Table(s), and Image(s).
• ►  Includes characters in the default headings Purpose, Methods, Results and Conclusions.
• ►  A Table/Image removes 320 characters from your character limit. The amount of data in the table does not make a difference to the character count.
• ►  Author names and institutions are not counted in the character limit.

REMINDERS

• ►  Proofread abstracts carefully to avoid errors before submission.
• ►  You may return to your abstract to make corrections to any portion of the abstract submission, including authors, up until the submission deadline.
• ►  Corrections are not permitted after the submission deadline.

A $25 (USD) processing fee must accompany each abstract. ISHLT accepts payment only in the form of MasterCard, Visa and American Express. Purchase orders, checks, and electronic bank transfers will not be accepted. This fee is non-refundable and used to cover the cost of submission and processing.

A disclosure statement must be collected from the Submitting Author. If the abstract is accepted, a disclosure will be collected from the Presenting Author (if different from the Submitting Author).

If all submission steps are completed, the submission is marked COMPLETE and no further action is required but abstracts can still be edited by the submitter until the deadline.

If one or more submission steps are not completed, the system will indicate which steps must be finished before the submission is marked COMPLETE.